Literature DB >> 2192793

Cytogenetics of human brain tumors.

S H Bigner1, J Mark, D D Bigner.   

Abstract

The most frequent cytogenetic alterations in primary brain tumors are losses of chromosomes or chromosomal regions and the presence of double minute chromosomes (dmins). The regions which are lost and the genes which are amplified are distinctive for individual tumor types. Most malignant gliomas contain gains of chromosome 7 and losses of chromosome 10; losses of chromosome 22, 9p, and the sex chromosomes occur in subgroups of cases. The gene most frequently amplified in tumors with dmins is the epidermal growth factor receptor gene. Medulloblastomas have losses of 17p and most cases with dmins have c-myc gene amplification. Meningiomas have losses or deletions of chromosome 22. Identification of these specific cytogenetic abnormalities in human brain tumors has provided the framework for identifying genes which are amplified in them and has identified chromosomal regions likely to contain tumor suppressor genes, the loss or inactivation of which is important in the development of these tumors.

Entities:  

Mesh:

Year:  1990        PMID: 2192793     DOI: 10.1016/0165-4608(90)90024-5

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  45 in total

1.  Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas.

Authors:  Nicolas Vogt; Sandrine-Hélène Lefèvre; Françoise Apiou; Anne-Marie Dutrillaux; Andrej Cör; Pascal Leuraud; Marie-France Poupon; Bernard Dutrillaux; Michelle Debatisse; Bernard Malfoy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-21       Impact factor: 11.205

2.  Nonrandom gain of chromosome 7 in central neurocytoma: a chromosomal analysis and fluorescence in situ hybridization study.

Authors:  D Taruscio; R Danesi; A Montaldi; S Cerasoli; G Cenacchi; F Giangaspero
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

3.  Transforming growth factor-alpha antisense vectors can inhibit glioma cell growth.

Authors:  P Tang; S A Jasser; J C Sung; Y Shi; P A Steck; W K Yung
Journal:  J Neurooncol       Date:  1999-06       Impact factor: 4.130

4.  Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas.

Authors:  Kinya Terada; Takashi Tamiya; Shigeru Daido; Hirokazu Kambara; Hiroaki Tanaka; Yasuhiro Ono; Kengo Matsumoto; Sachio Ito; Mamoru Ouchida; Takashi Ohmoto; Kenji Shimizu
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

5.  Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway.

Authors:  R A Gjerset; H Fakhrai; D L Shawler; S Turla; O Dorigo; A Grover-Bardwick; D Mercola; S F Wen; H Collins; H Lin
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-03       Impact factor: 2.416

6.  Patterns of epidermal growth factor receptor amplification in malignant gliomas.

Authors:  G Sauter; T Maeda; F M Waldman; R L Davis; B G Feuerstein
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

Review 7.  Genetic alterations in glioma and medulloblastoma.

Authors:  B K Rasheed; S H Bigner
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

8.  BCNU-sensitivity in parental cells and clones from four freshly resected near-diploid human gliomas: an astrocytoma, an anaplastic astrocytoma and two glioblastomas multiforme.

Authors:  J R Shapiro; S A Ebrahim; A N Mohamed; P Y Pu; W R Shapiro
Journal:  J Neurooncol       Date:  1993-03       Impact factor: 4.130

Review 9.  Molecular biology of pediatric gliomas.

Authors:  C Raffel
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

10.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

Authors:  J Reifenberger; G Reifenberger; L Liu; C D James; W Wechsler; V P Collins
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.